Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Adtalem shares positioned for continued growth, Baird maintains Outperform rating

EditorAhmed Abdulazez Abdulkadir
Published 2024-12-05, 11:34 a/m
ATGE
-

On Thursday, Baird, a financial services firm, raised its price target on Adtalem Global Education (NYSE:ATGE) stock to $100, up from the previous target of $93, while maintaining an Outperform rating. Currently trading at $91.64 and near its 52-week high of $92.93, the stock has delivered impressive returns with a 55.45% gain year-to-date.

The firm cites a positive outlook for sustainable mid-to-high single-digit percentage revenue growth due to self-improvement measures and structural demand dynamics. The analyst believes that the stock presents an attractive risk/reward scenario, though InvestingPro analysis suggests the stock is slightly overvalued at current levels.

Adtalem, a provider of workforce solutions, is reportedly in the early stages of its "Growth with Purpose" strategy, which aims to drive organic growth over a three-year period. The strategy appears to be working, with revenue growing 11.45% over the last twelve months and maintaining strong profitability with a 56.16% gross margin.

This strategy has shown positive results thus far, and there is potential for sustained growth beyond fiscal year 2026. The company is expected to benefit from structural drivers and capitalize on its position as a scaled provider addressing critical healthcare employment shortages.

The analyst from Baird suggests that if Adtalem continues its strong execution, its shares could close the valuation gap compared to other high-quality peers. This is partly due to Adtalem's attractive business model. The current regulatory environment is also seen as manageable and potentially net favorable following the election of Donald Trump.

Adtalem has been focused on addressing the significant demand for healthcare professionals through its educational services. The company's efforts to meet the employment needs in the healthcare sector are particularly relevant given the ongoing shortages in the industry. This strategic positioning is expected to contribute to the company's revenue growth and the analyst's positive outlook on the stock's future performance.

Investors and market watchers will likely monitor Adtalem's progress as it continues to implement its growth strategy and respond to the evolving needs of the healthcare employment market. InvestingPro has identified several additional bullish indicators for ATGE, including management's aggressive share buybacks and the company's moderate debt levels.

For deeper insights into Adtalem's financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers, which provides detailed analysis of all key metrics and growth drivers.

In other recent news, Adtalem Global Education Inc. has reported a robust start to fiscal year 2025, marked by significant growth in revenue and earnings per share. The company's Q1 FY2025 earnings revealed a 13% year-over-year increase in revenue to $417 million and a 39% rise in adjusted earnings per share to $1.29. Adtalem also announced an upward adjustment of its FY2025 revenue guidance to a range of $1.69 billion to $1.73 billion, and adjusted EPS guidance to $5.75–$5.95.

This positive performance is attributed to a 11.2% increase in total enrollment, now exceeding 90,000 students. The company's strategic investments, particularly in marketing and the expansion of nursing programs, have also contributed to this growth.

Despite a slight year-over-year decrease in adjusted EBITDA margin by 70 basis points to 21.8%, the company demonstrated strong cash flow, reporting $79 million for the quarter. These developments are part of Adtalem's "Growth with Purpose" strategy, reflecting its commitment to expanding educational offerings and addressing the healthcare shortage.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.